Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
September 15, 2014

The 10 Top Paid Women Executives in Biopharma

A new industry leader reigns supreme this year.

The 10 Top Paid Women Executives in Biopharma

Find out which female exec earned the most in compensation in 2013. [© stefa_neve - Fotolia.com]

  • Since last week’s GEN List of What the Top 20 Biopharma CEOs Are Making was headed by a woman, it stands to reason that she also heads this week’s GEN List, focused on the Top 10 Paid Women Executives.

    Yet despite being the first-ever woman to top the CEO list, this year’s top-compensated woman executive is more the exception than the rule. All nine women listed under her received total compensation of less than $10 million—compared to the $11 million and up awarded to last week’s top-20 CEOs, only one of which was a woman. And only the top two-paid women executives on this list were CEOs; the rest held a variety of senior managerial titles that included “VP,” “chair,” and “head” positions.

    Of four other women CEOs not paid highly enough for this list, but whose total compensation could still be ranked among the top 30 highest-paid women executives, the highest was NeoStem CEO and Chairman Robin L. Smith, M.D., who received $1,235,500. The other three were paid less than $1 million. A fifth woman CEO was not compensated in 2013 (Michelle Dipp, M.D., Ph.D., CEO and co-founder of OvaScience).

    Following is this year’s list, which ranks top women executives at public biopharma companies by their total 2013 compensation as disclosed in company proxy statements. Each executive is listed by name, title, company, 2013 and 2012 total compensation, and percent change between the two years. All non-U.S. currencies have been converted to U.S. dollars.

  • #10. Kristin C. Peck

    Company: Zoetis

    Title: EVP and Group President

    2013 total compensation: $3,293,458

    2012 total compensation: $2,278,413

    % Change: 44.6%

  • #9. Robin L. Washington

    Company: Gilead Sciences

    Title: EVP and CFO

    2013 total compensation: $3,941,728

    2012 total compensation: $4,175,593

    % Change: -5.6%

  • #8. Mahkam (Maky) Zanganeh, D.D.S., M.B.A.

    Company: Pharmacyclics

    Title: COO

    2013 total compensation: $4,711,167

    2012 total compensation: $5,798,452

    % Change: -18.8%

  • #7. Sandra Leung

    Company: Bristol-Myers Squibb

    Title: General Counsel and Corporate Secretary

    2013 total compensation: $4,816,287

    2012 total compensation: $5,892,772

    % Change: -18.3%

  • #6. Silvia Ayyoubi

    Company: Roche

    Title: Head Group Human Resources

    2013 total compensation: $5,434,448 (CHF 5,095,086)

    2012 total compensation: $5,076,326 (CHF 4,759,151)

    % Change: 7.1%

  • #5. Sandra Peterson

    Company: Johnson & Johnson

    Title: Group Worldwide Chair

    2013 total compensation: $5,637,261

    2012 total compensation: $4,698,850

    % Change: 20.0%

  • #4. Laura J. Schumacher

    Company: AbbVie

    Title: EVP, Business Development, External Affairs, and General Counsel

    2013 total compensation: $6,996,2981

    2012 total compensation: $10,192,7482

    % Change: -31.4%

  • #3. Jacqualyn A. Fouse, Ph.D.

    Company: Celgene

    Title: EVP and CFO

    2013 total compensation: $7,795,941

    2012 total compensation: $3,450,103

    % Change: 126.0%

  • #2. Heather Bresch

    Company: Mylan

    Title: CEO

    2013 total compensation: $8,707,958

    2012 total compensation: $8,000,628

    % Change: 8.8%

  • #1. Martine Rothblatt, Ph.D., J.D., M.B.A.

    Company: United Therapeutics

    Title: Chairman and CEO

    2013 total compensation: $38,218,2553,4

    2012 total compensation: $7,958,3284

    % Change: 380.2%

Related content